Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00843089 · ClinicalTrials.gov registry record · NA

Secondary Prevention After Coronary Bypass Surgery

A NA study of Coronary Artery Disease, sponsored by Jeffrey Kramer, MD.

Completed
Registry status
NA
Development phase
115
Enrollment target
1
Study location

NCT00843089: Completed NA study of Coronary Artery Disease, sponsored by Jeffrey Kramer, MD.

NCT00843089 is a NA study of Coronary Artery Disease that has completed, run by Jeffrey Kramer, MD. The registered enrollment target is 115 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00843089, a NA study of Coronary Artery Disease, has completed, sponsored by Jeffrey Kramer, MD.

COMPLETED
Registry status
NA
Development phase
115 participants
Enrollment target
1
Study location

Study Summary

Despite immediate symptomatic success after coronary bypass surgery in patients with coronary artery disease, this effect is not sustained over time since risk factors for coronary artery disease are still in place. The role of secondary prevention becomes increasingly important as it can potentially decrease or eliminate the need for another intervention in these high risk subjects. This project seeks to evaluate the effect of emphasizing secondary prevention measures in this patient population during hospital admission and through six months post-discharge.

Conditions Studied

Interventions

  • OTHER Education

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2009-01
Est. Completion 2013-06
Phase NA
Jeffrey Kramer, MD

1 total trials

What the finished NCT00843089 record still lists

NCT00843089 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Education is the first listed.

NCT00843089 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT00843089 about?

NCT00843089 is a clinical study titled "Secondary Prevention After Coronary Bypass Surgery". Despite immediate symptomatic success after coronary bypass surgery in patients with coronary artery disease, this effect is not sustained over time since risk factors for coronary artery disease are still in place. The role of secondary prevention becomes increasingly important as it can potentiall...

What is the current status of trial NCT00843089?

This trial is currently completed. It is a NA study. The enrollment target is 115 participants. The study started on 2009-01. Estimated completion is 2013-06.

What conditions does trial NCT00843089 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT00843089?

The interventions under investigation include: Education (OTHER).

Who is sponsoring clinical trial NCT00843089?

This trial is sponsored by Jeffrey Kramer, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00843089 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00843089's enrollment target sits among peer trials

115 140th of 219 higher than 80 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02346929 · 115 participants · NA

    Hematoma Block for Distal Radius Fracture

  • NCT03394365 · 115 participants · Phase 3

    A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

  • NCT03907475 · 115 participants · Phase 2

    Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

  • NCT05086692 · 115 participants · Phase 1

    A Beta-only IL-2 ImmunoTherapY Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00843089, the US trial registry maintained by the National Library of Medicine. NCT00843089 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.